SCHEMBL4488785

SCHEMBL4488785

CCOC(=O)c1[nH]nc2c1CC1C2C1C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 1/20 0.38
▸ MAPK10 P53779 1/20 0.38
▸ RIPK1 Q13546 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.36
▸ PDE4D Q08499 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ HCAR2 Q8TDS4 5/20 0.35
▸ LMNA P02545 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4487593 0.84 HCAR2 (0.43) AURKAMAPK10RIPK1HSD17B10PDE4D
SCHEMBL13631562 0.84 HCAR2 (0.43) AURKAMAPK10RIPK1HSD17B10PDE4D
SCHEMBL13631567 0.84 HCAR2 (0.43) AURKAMAPK10RIPK1HSD17B10PDE4D
SCHEMBL4500770 0.84 HCAR2 (0.43) AURKAMAPK10RIPK1HSD17B10PDE4D
SCHEMBL4488769 0.83 HCAR2 (0.49) AURKAMAPK10RIPK1HSD17B10PDE4D
SCHEMBL4491886 0.82 HCAR2 (0.47) AURKAMAPK10RIPK1HSD17B10PDE4D
SCHEMBL13631571 0.82 HCAR2 (0.47) AURKAMAPK10RIPK1HSD17B10PDE4D
SCHEMBL4477061 0.82 HCAR2 (0.47) AURKAMAPK10RIPK1HSD17B10PDE4D
SCHEMBL13631789 0.81 HCAR2 (0.34) HCAR2
SCHEMBL4488486 0.81 HCAR2 (0.39) HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612106-B2 Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof ARENA PHARMACEUTICALS, INC. (US) 2009-11-03 — — US disclosed
US-20090258892-A1 FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF ARENA PHARMACEUTICALS, INC. (US) 2009-10-15 — — US disclosed
US-7241792-B2 Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof ARENA PHARMACEUTICALS, INC. (US) 2007-07-10 — — US disclosed
US-20070073062-A1 Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof ARENA PHARMACEUTICALS, INC. 2007-03-29 — — US disclosed
US-20060205955-A1 Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof ARENA PHARMACEUTICALS, INC. (US) 2006-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258892-A1 FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF ACE, ACE2, AGTR2 AURKA 3931/4885MAPK10 4448/4885RIPK1 1699/4885
US-20070073062-A1 Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof ACE, ACE2, AGTR2 AURKA 3931/4885MAPK10 4448/4885RIPK1 1699/4885
US-20060205955-A1 Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof ACE, ACE2, AGTR2 AURKA 3931/4885MAPK10 4448/4885RIPK1 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback